mRNA vaccine plus pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can follow the study plan
- You have advanced (locally advanced, recurrent, or metastatic) solid cancer that has worsened or is not suitable for standard treatment
- Your tumor test must show specific HLA and gene findings that suggest your immune system can recognize the cancer (based on sequencing and lab tissue testing)
- You must have measurable cancer on scans and a life expectancy of at least 4 months
- You must have good overall health based on blood/organ tests and good heart-lung status, and avoid certain medicines like chemo or steroids close to enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
This trial tests a new mRNA-based treatment injected directly into solid tumors that haven't responded to standard therapy. The goal is to help your immune system recognize and attack cancer cells.
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.